The mechanisms that link altered metabolism and heart failure remain unclear. A new study defines the role of the lysine demethylase KDM8 in preventing the initiation of dilated cardiomyopathy through epigenetic control of homeostatic cardiac metabolism.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Yu, J., Zeng, C. & Wang, Y. Curr. Opin. Cardiol. 34, 260–269 (2019).
Berry, J. M., Cao, D. J., Rothermel, B. A. & Hill, J. A. Expert Opin. Drug Saf. 7, 53–67 (2008).
Papait, R., Serio, S. & Condorelli, G. Physiol. Rev. 100, 1753–1777 (2020).
Hyun, K., Jeon, J., Park, K. & Kim, J. Exp. Mol. Med. 49, e324 (2017).
Hsia, D. A. et al. Proc. Natl Acad. Sci. USA 107, 9671–9676 (2010).
Wang, H. J. et al. Oncogene 38, 17–32 (2019).
Ahmed, A. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00214-0 (2023).
Keating, S. T. & El-Osta, A. Circ. Res. 116, 715–736 (2015).
Yu, J. R. et al. Sci. Adv. 7, eabg7444 (2021).
Pepin, M. E. et al. Lab. Invest. 99, 371–386 (2019).
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bakshi, S., Wende, A.R. KDM8 prevents heart failure by controlling cardiac metabolism. Nat Cardiovasc Res 2, 106–107 (2023). https://doi.org/10.1038/s44161-023-00229-7